We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Bio Rad Laboratories Inc (BIO) Class A Com Stk USD1

Sell:$287.34 Buy:$287.35 Change: $3.04 (1.05%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $3.04 (1.05%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $3.04 (1.05%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Contact details

United States
+1 (510) 7247000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$8.26 billion
Shares in issue:
28.52 million
Life Sciences Tools & Services
New York Stock Exchange
United States
US dollar

Key personnel

  • Norman Schwartz
    Chairman of the Board, President, Chief Executive Officer
  • Roop Lakkaraju
    Chief Financial Officer, Executive Vice President, Principal Financial officer
  • Andrew Last
    Chief Operating Officer, Executive Vice President
  • Colleen Corey
    Executive Vice President Global Human Resources
  • James Barry
    Executive Vice President, President - Life Science Group
  • Michael Crowley
    Executive Vice President - Global Commercial Operations
  • Sedat Evran
    Executive Vice President - Global Supply Chain

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.